# Harsha Raghavan

> Harsha Raghavan is a post-ipo equity investor at Convergent Finance backing Manufacturing. See 11 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Convergent Finance](https://shizune.co/investors/profile/convergent-finance)
- Location: Mumbai, India
- Total investments: 11
- Last investment: Sep 2023
- Lead investor: 91%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/harsha-raghavan-1218a11b5

Harsha Raghavan is a post-ipo equity investor at Convergent Finance in Mumbai focused on Manufacturing and Biotechnology. Harsha Raghavan is the Founder & Managing Partner of Convergent Finance & he attended Stanford University Graduate School of Business in 2004. Harsha previously worked at STEER CAPITAL as Founding MD.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Manufacturing | 4 | 36% |
| Biotechnology | 3 | 27% |
| Pharmaceutical | 3 | 27% |
| Cosmetics | 2 | 18% |
| Life Science | 2 | 18% |

20 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Equity | 6 | 55% |
| Private Equity | 2 | 18% |
| Series A | 1 | 9% |
| Post-IPO Secondary | 1 | 9% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| India | 9 | 82% |
| United Kingdom | 1 | 9% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Camlin Fine Sciences | Camlin Fine Sciences is a provider of high-quality shelf life extension solutions including antioxidants, aroma ingredients and performance chemicals. |  | Post-IPO Equity | Sep 15, 2023 |  |
| Agilitas | Agilitas Sports operates as a sportswear and athleisure solutions platform. | $52.3M | Series A | May 15, 2023 |  |
| Fly91 | Fly91provides reliable, comfortable and affordable flights. | $24.3M | Private Equity | Jan 09, 2023 |  |
| Jagsonpal Pharmaceuticals | Jagsonpal Pharmaceuticals is a pharma company that specializes in the development of bulk drugs and pharmaceutical formulations. It has a presence in gynaecology, IVF specialization, and orthopedics. Their drug engagement is in women's health, pain, analgesics, and general medicine. | $35.9M | Post-IPO Equity | Feb 21, 2022 |  |
| Onward Technologies | Headquartered in Mumbai, with prominent global presence in North America & Europe, and state-of-the-art offshore delivery centres (ODC) in India, we support businesses in focused verticals of Transportation & Mobility, Industrial Equipment & Heavy Machinery, and Healthcare & Lifesciences. With a scalable outsourcing/offshoremodel across 6 countries, a fast-growing team of 2800+ employees, and long-term customer associations, we accelerate innovation and maximize returns on R&D investments for our marquee customers. With two decades of expertise in Mechanical Engineering capabilities, we have augmented our prowess in two lines of business (LOB) in Digital & Data Engineering and Electronics & Embedded Engineering for our customers. Founded in 1991, the company has been listed on both NSE and BSE, since 1995. | $9.7M | Post-IPO Equity | May 27, 2021 |  |
| Borosil Renewables | Borosil is a market leader for laboratory glassware for India’s leading pharmaceutical and healthcare sectors. Borosil plans to combine its technological expertise in speciality glass production with Klasspack’s experience in glass ampoule and tubular glass vial production. | $27.2M | Post-IPO Equity | Dec 18, 2020 |  |
| ADF Foods | ADF Foods focus on prepared ethnic food offering ready-to-eat items, ready-to-cook items, sauces, pickles, pastes, dips and frozen foods. | $11.9M | Post-IPO Secondary | Dec 04, 2020 |  |
| SeQuent Scientific | SeQuent Scientific Limited is an India-based integrated pharmaceutical company. The Company engaged in developing products and services for a variety of industries, such as pharmaceuticals, agrochemicals, plastics, personal care (cosmetics). The Company operates in three segments include active pharmaceutical ingredients (API), Analytical Servicesand Animal Health. | $15.5M | Post-IPO Equity | Jun 29, 2020 |  |
| Viyash Lifesciences | Viyash Lifesciences is an India-based integrated pharmaceutical company. The Company engaged in developing products and services for a variety of industries, such as pharmaceuticals, agrochemicals, plastics, personal care (cosmetics). The Company operates in three segments include active pharmaceutical ingredients (API), Analytical Services andAnimal Health. | $17.2M | Post-IPO Equity | Jun 29, 2020 |  |
| Camlin Fine Sciences | Camlin Fine Sciences is a provider of high-quality shelf life extension solutions including antioxidants, aroma ingredients and performance chemicals. | $23.8M | Post-IPO Equity | Jun 25, 2020 |  |

10 of 11 investments shown.

## About Convergent Finance

VC Fund · Mumbai, India

Convergent is an investment partnership at the forefront of bringing together Ideas, Capital and passionate Entrepreneurs. We help great companies transform into global leaders. The Convergent investment process involves identifying proprietary platform and bolt-on opportunities, speed of execution and a relentless focus on performance improvement.The Convergent value investing approach believes in paying fair and reasonable valuations through bilaterally negotiated transactions.

1 contacts available at Convergent Finance.

| Name | Title | Profile |
| --- | --- | --- |
| Harsha Raghavan | Founder & Managing Partner | https://shizune.co/investors/profile/harsha-raghavan |

## Similar investors

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

## FAQ

### What does Harsha Raghavan invest in?

Harsha Raghavan invests primarily in Manufacturing, Biotechnology and Pharmaceutical startups, most often at Post-IPO Equity and Private Equity stage. Most of the 11 investments tracked by Shizune back companies in India. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Harsha Raghavan last invest?

The most recent investment recorded for Harsha Raghavan closed in Sep 2023. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co